The trend of old Dragon Ball villains making returns with fancy new forms raises some interesting questions about what former ...

The cover of Dragon Ball Super Vol. 24 has sent shockwaves through the fandom with one of the most exciting group shots in ...

Dragon Ball has its fair share of realms, dimensions, and universes, which was further expanded with the Dragon Ball Super ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $93.00. The company’s shares closed yesterday at $46.22.

In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC ...

Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length ...

In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m ...

When it comes to monumental anime history, it's essential to acknowledge the late Akira Toriyama's most beloved anime franchise, Dragon Ball. Based on the manga from Toriyama, the original series ...

TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET The webcasts of the presentations will be ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

Merus has a 1 year low of $37.77 and a 1 year high of $61.61. The company has a market capitalization of $3.20 billion, a P/E ratio of -11.84 and a beta of 1.11. A number of analysts have issued ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...